All News
Filter News
Found 772 articles
-
Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
1/3/2018
This marks the expansion of the clinical development program for OPT-302 into a second ocular indication and targets a severe complication of diabetes.
-
Inovio Pharmaceuticals Reports 2017 Third Quarter Financial Results
11/9/2017
Total revenue was $2.6 million for the three months ended September 30, 2017, compared to $12.5 million for the same period in 2016.
-
Inovio Pharmaceuticals Begins Phase Ib/II Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer
10/16/2017
Inovio announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab in combination with Inovio’s INO-5401 and INO-9012.
-
3M Company And Biotech Week Boston Partner To Connect Women In Bioprocessing With Leadership Roundtable
9/22/2017
-
Uptake Of Sanofi/Regeneron's Dupixent For Atopic Dermatitis Strong, But Sales Representative Contact Rates Leave Something To Be Desired
8/22/2017
-
Opthea Presents Additional Positive Data From OPT-302 Phase I/IIa Wet AMD Trial At ASRS Meeting
8/16/2017
-
Ophthotech's Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study
8/15/2017
-
Opthea To Present At The American Society Of Retinal Specialists Annual Meeting And The Ophthalmology Innovation Summit
8/15/2017
-
Opthea Receives Notice Of Allowance For Key Patent Covering OPT-302 In The United States
7/6/2017
-
Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical Officer
6/28/2017
-
Novartis AG's Next-Generation Eye Drug Works With Fewer Injections Than Rivals
6/21/2017
-
What do life sciences professionals value in an employer? According to the first annual 2017 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a ...
-
Sanofi Commits $673 Million in Biologics
6/14/2017
-
Inovio Pharma Announces Clinical Trial Collaboration To Evaluate A Novel T-Cell Immunotherapy In Combination With A PD-L1 Checkpoint Inhibitor
6/1/2017
-
These 3 Biotechs Could Lead the Next Biotech Boom
5/24/2017
-
Opthea Completes A $45 Million Capital Raising
5/2/2017
-
Opthea Reports Positive Phase I/IIA Clinical Results For OPT-302 In Wet AMD
4/3/2017
-
Opthea Conference Call/Webcast -- Update On OPT-302 Phase 1/2A Wet AMD Clinical Trial
3/31/2017
-
Opthea Receives Positive Feedback From European Regulatory Agencies For The OPT-302 Clinical Program In Wet AMD
3/20/2017